Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rodrigo Fresco

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Acta Ortopedica Brasileira|March 22, 2016
EPIDEMIOLOGY AND TREATMENT OF MONTEGGIA LESION IN ADULTS: SERIES OF 44 CASESRoberto Suarez, Antonio Barquet, Rodrigo Fresco
Tumori|August 12, 2003
Synchronous presentation of an Askin tumor and a plasmacytoma in an adult patientRodrigo Fresco, Lyber Saldombide, Liliana Suárez
Epidemiology (Cambridge, Mass.)|May 18, 2018
The Authors RespondGonzalo Spera, Rodrigo Fresco, Helena Fung, et al.
The Oncologist|May 31, 2015
Imaging Radiation Doses and Associated Risks and Benefits in Subjects Participating in Breast Cancer Clinical TrialsRodrigo Fresco, Gonzalo Spera, Carlos Meyer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2015
Reply to H.J. Lee et alJohn R Mackey, Vincent Houé, Francois Thireau, et al.
Clinical Breast Cancer|March 10, 2019
Intensive Imaging Surveillance of Survivors of Breast Cancer May Increase Risk of Radiation-induced MalignancyCarlos Meyer, Pablo Millán, Valeria González, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 3, 2016
Final Survival Analysis of ROSE/TRIO-012John R Mackey, Nicole McCarthy, Karen A Gelmon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 28, 2025
Health-Related Quality of Life in Patients with HR+/HER2- Early Breast Cancer Treated with Ribociclib Plus a Nonsteroidal Aromatase Inhibitor: Results from the NATALEE TrialPeter A Fasching, Dennis Slamon, Zbigniew Nowecki, et al.
The Lancet. Oncology|November 28, 2017
Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trialSara A Hurvitz, Miguel Martin, W Fraser Symmans, et al.
JAMA Oncology|September 25, 2025
Ribociclib Plus Endocrine Therapy in Hormone Receptor-Positive/ERBB2-Negative Early Breast Cancer: 4-Year Outcomes From the NATALEE Randomized Clinical TrialPeter A Fasching, Daniil Stroyakovskiy, Denise A Yardley, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Acta Ortopedica Brasileira|March 22, 2016
EPIDEMIOLOGY AND TREATMENT OF MONTEGGIA LESION IN ADULTS: SERIES OF 44 CASESRoberto Suarez, Antonio Barquet, Rodrigo Fresco
Tumori|August 12, 2003
Synchronous presentation of an Askin tumor and a plasmacytoma in an adult patientRodrigo Fresco, Lyber Saldombide, Liliana Suárez
Epidemiology (Cambridge, Mass.)|May 18, 2018
The Authors RespondGonzalo Spera, Rodrigo Fresco, Helena Fung, et al.
The Oncologist|May 31, 2015
Imaging Radiation Doses and Associated Risks and Benefits in Subjects Participating in Breast Cancer Clinical TrialsRodrigo Fresco, Gonzalo Spera, Carlos Meyer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2015
Reply to H.J. Lee et alJohn R Mackey, Vincent Houé, Francois Thireau, et al.
Clinical Breast Cancer|March 10, 2019
Intensive Imaging Surveillance of Survivors of Breast Cancer May Increase Risk of Radiation-induced MalignancyCarlos Meyer, Pablo Millán, Valeria González, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 3, 2016
Final Survival Analysis of ROSE/TRIO-012John R Mackey, Nicole McCarthy, Karen A Gelmon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 28, 2025
Health-Related Quality of Life in Patients with HR+/HER2- Early Breast Cancer Treated with Ribociclib Plus a Nonsteroidal Aromatase Inhibitor: Results from the NATALEE TrialPeter A Fasching, Dennis Slamon, Zbigniew Nowecki, et al.
The Lancet. Oncology|November 28, 2017
Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trialSara A Hurvitz, Miguel Martin, W Fraser Symmans, et al.
JAMA Oncology|September 25, 2025
Ribociclib Plus Endocrine Therapy in Hormone Receptor-Positive/ERBB2-Negative Early Breast Cancer: 4-Year Outcomes From the NATALEE Randomized Clinical TrialPeter A Fasching, Daniil Stroyakovskiy, Denise A Yardley, et al.
Pageof 2